Susan McLaughlin
Fox Chase Cancer Center
9 Papers
95 Citations
Susan McLaughlin is an academic researcher from Fox Chase Cancer Center. The author has contributed to research in topics: Medicine & Immunology. The author has an hindex of 8, co-authored 9 publications. Previous affiliations of Susan McLaughlin include Johnson & Johnson Pharmaceutical Research and Development.
Chat about Author
Papers
•Journal Article
Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 Transgenes in patients with recurrent CEA-expressing adenocarcinomas
Margaret von Mehren,Philip M. Arlen,Kwong Y. Tsang,Andre Rogatko,Neal J. Meropol,Harry S. Cooper,Monica Davey,Susan McLaughlin,Jeffrey Schlom,Louis M. Weiner +9 more
TL;DR: The vaccine ALVAC-CEA B7.1 is safe in patients with advanced, recurrent adenocarcinomas that express CEA, and it is associated with the induction of a CEA-specific T-cell response.
187
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
Steven J. Cohen,Linus Ho,Sulabha Ranganathan,James L. Abbruzzese,R. Katherine Alpaugh,Mary Beard,Nancy L. Lewis,Susan McLaughlin,Andre Rogatko,Juan J. Perez-Ruixo,Amanda M. Thistle,Tom Verhaeghe,Hao Wang,L. M. Weiner,John J. Wright,Gary R. Hudes,N. J. Meropol +16 more
TL;DR: Although treatment with R115777 resulted in partial inhibition of FTase activity in mononuclear cells, it did not exhibit single-agent antitumor activity in patients with previously untreated metastatic pancreatic cancer.
175
Phase II Trial of Dolastatin-10, a Novel Anti-Tubulin Agent, in Metastatic Soft Tissue Sarcomas
M. von Mehren,S. P. Balcerzak,A. S. Kraft,J. H. Edmonson,S. H. Okuno,Monica Davey,Susan McLaughlin,Mary Beard,Andre Rogatko +8 more
TL;DR: Dol-10 was associated with hematological toxicity and with some vascular toxicities, and further study of Dol-10 on this schedule is not recommended in advanced or metastatic soft tissue sarcomas.
Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer : A phase II report
Leonard R. Henry,Melvyn Goldberg,Walter J. Scott,Andre Konski,Neal J. Meropol,Gary M. Freedman,Louis M. Weiner,Perry Watts,Mary Beard,Susan McLaughlin,Jonathan D. Cheng +10 more
TL;DR: This regimen of multimodality therapy before resection resulted in an encouraging 2-year survival rate but a disappointing rate of pathologic complete response and was toxic, necessitating a predetermined paclitaxel dose reduction.
36
Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.
Crystal S. Denlinger,Rebecca L. Blanchard,Rebecca L. Blanchard,Lu Xu,Coen Bernaards,Samuel Litwin,Cynthia S. Spittle,Daniel J. Berg,Susan McLaughlin,Maryann Redlinger,Andrew Dorr,Julie Hambleton,S. N. Holden,Anne Kearns,Sara Kenkare-Mitra,Bert L. Lum,Neal J. Meropol,Peter J. O'Dwyer +17 more
TL;DR: Bevacizumab does not affect irinotecan PK when administered concurrently, and a variety of pharmacogenetic relationships may influence the pharmacokinetics of irinOTecan and its toxicity.
33